“B-Cell Lymphomas Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the B-Cell Lymphomas Market.
The B-Cell Lymphomas Pipeline report embraces in-depth commercial, regulatory, and B-Cell Lymphomas clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging B-Cell Lymphomas drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
B-Cell Lymphomas Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for B-Cell Lymphomas treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different B-Cell Lymphomas therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major B-Cell Lymphomas companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the B-Cell Lymphomas drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the B-Cell Lymphomas therapeutic market.
B-Cell Lymphomas Therapeutics Landscape
There are approx. 160+ key companies developing therapies for B-cell lymphoma. Currently, ZAI Lab is leading the therapeutics market with its B-Cell Lymphoma drug candidates in the most advanced stage of clinical development.
B-Cell Lymphomas Companies Actively Working in the Therapeutic Market Include:
Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and many others
Emerging and Marketed B-Cell Lymphomas Drugs Covered in the Report Include:
-
Odronextamab: ZAI Lab
-
NKTR-255: Nektar Therapeutics
-
Zilovertamab Vedotin: Merck Sharp & Dohme LLC
-
Abexinostat: Xynomic Pharmaceuticals
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and B-cell lymphoma companies Working in the Market @
https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight
Analysis of Emerging B-Cell Lymphomas Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
intravenous
-
Subcutaneous
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the B-Cell Lymphomas Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. B-Cell Lymphomas Treatment Patterns
4. B-Cell Lymphomas – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. B-Cell Lymphomas Late Stage Products (Phase-III)
7. B-Cell Lymphomas Mid-Stage Products (Phase-II)
8. B-Cell Lymphomas Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-Cell Lymphomas Discontinued Products
13. B-Cell Lymphomas Product Profiles
14. Major B-Cell Lymphoma Companies in the Market
15. Key Products in the B-Cell Lymphomas Therapeutics Segment
16. Dormant and Discontinued Products
17. B-Cell Lymphomas Unmet Needs
18. B-Cell Lymphomas Future Perspectives
19. B-Cell Lymphomas Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Overt Hepatic Encephalopathy Market
“Overt Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Overt Hepatic Encephalopathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Overt Hepatic Encephalopathy market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/